伴有突变的G-CSF产生型肺癌的治疗耐药性
Therapeutic Resistance in G-CSF Producing Lung Cancer With Mutation.
作者信息
Ito Koki, Kaira Kyoichi, Imai Hisao, Shiono Ayako, Hashimoto Kosuke, Yamaguchi O U, Kagamu Hiroshi
机构信息
Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
出版信息
Cancer Diagn Progn. 2024 Jul 3;4(4):529-533. doi: 10.21873/cdp.10359. eCollection 2024 Jul-Aug.
BACKGROUND/AIM: Granulocyte colony-stimulating factor (G-CSF)-producing neoplasms are relatively rare; however, little is known on the clinical features of G-CSF-producing lung cancer harboring activating epidermal growth factor receptor (EGFR) mutations.
CASE REPORT
A 66-year-old female was definitively diagnosed with G-CSF-producing lung cancer that was positive for EGFR mutations. She repeatedly received epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as osimertinib and afatinib. However, she developed resistance to these molecular-targeting drugs within 2 to 3 months after immediate shrinkage. Thus, the patient was treated with chemoimmunotherapy including bevacizumab, and demonstrated a slight survival benefit.
CONCLUSION
Overall, G-CSF-producing lung cancers positive for EGFR mutations were resistant to different treatment modalities. Clinicians should be attentive to the potential resistance of G-CSF-producing EGFR mutant lung cancer to EGFR-TKI therapy.
背景/目的：产生粒细胞集落刺激因子（G-CSF）的肿瘤相对罕见；然而，对于携带激活型表皮生长因子受体（EGFR）突变的产生G-CSF的肺癌的临床特征知之甚少。
病例报告
一名66岁女性被确诊为产生G-CSF的肺癌，EGFR突变呈阳性。她反复接受表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）治疗，如奥希替尼和阿法替尼。然而，在肿瘤立即缩小后的2至3个月内，她对这些分子靶向药物产生了耐药性。因此，该患者接受了包括贝伐单抗在内的化疗免疫治疗，并显示出轻微的生存获益。
结论
总体而言，EGFR突变阳性的产生G-CSF的肺癌对不同治疗方式均耐药。临床医生应注意产生G-CSF的EGFR突变型肺癌对EGFR-TKI治疗的潜在耐药性。
Zotero 插件